作者
James Shepherd, Gerard J Blauw, Michael B Murphy, Edward LEM Bollen, Brendan M Buckley, Stuart M Cobbe, Ian Ford, Allan Gaw, Michael Hyland, J Wouter Jukema, Adriaan M Kamper, Peter W Macfarlane, A Edo Meinders, John Norrie, Chris J Packard, Ivan J Perry, David J Stott, Brian J Sweeney, Gillian Twomey, Rudi GJ Westendorp
发表日期
2002/11/23
期刊
The Lancet
卷号
360
期号
9346
页码范围
1623-1630
出版商
Elsevier
简介
Background
Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-aged individuals, their efficacy and safety in elderly people is not fully established. Our aim was to test the benefits of pravastatin treatment in an elderly cohort of men and women with, or at high risk of developing, cardiovascular disease and stroke.
Methods
We did a randomised controlled trial in which we assigned 5804 men (n=2804) and women (n=3000) aged 70–82 years with a history of, or risk factors for, vascular disease to pravastatin (40 mg per day; n=2891) or placebo (n=2913). Baseline cholesterol concentrations ranged from 4·0 mmol/L to 9·0 mmol/L. Follow-up was 3·2 years on average and our primary endpoint was a composite of coronary death, non-fatal myocardial infarction, and fatal or non-fatal stroke. Analysis was by intention-to-treat.
Findings
Pravastatin lowered LDL cholesterol concentrations by …
引用总数
学术搜索中的文章
J Shepherd, GJ Blauw, MB Murphy, ELEM Bollen… - The Lancet, 2002
PROspective Study of Pravastatin in the Elderly at Risk … - Lancet, 2002
J Shepherd, GJ Blauw, MB Murphy, EL Bollen… - Lancet, 2002